Literature DB >> 20840064

Multiple defects in energy metabolism in Alzheimer's disease.

I L Ferreira1, R Resende, E Ferreiro, A C Rego, C F Pereira.   

Abstract

Alzheimer's disease (AD) is the most common form of dementia in old age. Cognitive impairment in AD may be partially due to overall hypometabolism. Indeed, AD is characterized by an early region-specific decline in glucose utilization and by mitochondrial dysfunction, which have deleterious consequences for neurons through increased production of reactive oxygen species (ROS), ATP depletion and activation of cell death processes. In this article, we provide an overview of the alterations on energetic metabolism occurring in AD. First, we resume the evidences that link the 'metabolic syndrome' with increased risk for developing AD and revisit the major changes occurring on both extra-mitochondrial and mitochondrial metabolic pathways, as revealed by imaging studies and biochemical analysis of brain and peripheral samples obtained from AD patients. We also cover the recent findings on cellular and animal models that highlight mitochondrial dysfunction as a fundamental mechanism in AD pathogenesis. Recent evidence posits that mitochondrial abnormalities in this neurodegenerative disorder are associated with changes in mitochondrial dynamics and can be induced by amyloid-beta (Aβ) that progressively accumulates within this organelle, acting as a direct toxin. Furthermore, Aβ induces activation of glutamate N-methyl-D-aspartate receptors (NMDARs) and/or excessive release of calcium from endoplasmic reticulum (ER) that may underlie mitochondrial calcium dyshomeostasis thereby disturbing organelle functioning and, ultimately, damaging neurons. Throughout the review, we further discuss several therapeutic strategies aimed to restore neuronal metabolic function in cellular and animal models of AD, some of which have reached the stage of clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20840064     DOI: 10.2174/1389450111007011193

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  68 in total

1.  Cardiorespiratory response to exercise testing in individuals with Alzheimer's disease.

Authors:  Sandra A Billinger; Eric D Vidoni; Robyn A Honea; Jeffrey M Burns
Journal:  Arch Phys Med Rehabil       Date:  2011-12       Impact factor: 3.966

Review 2.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 3.  Bioenergy sensing in the brain: the role of AMP-activated protein kinase in neuronal metabolism, development and neurological diseases.

Authors:  Stephen Amato; Heng-Ye Man
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

4.  Sulfuretin protects hepatic cells through regulation of ROS levels and autophagic flux.

Authors:  Yu-Ting Lu; Yu-Feng Xiao; Yu-Feng Li; Jia Li; Fa-Jun Nan; Jing-Ya Li
Journal:  Acta Pharmacol Sin       Date:  2018-12-18       Impact factor: 6.150

Review 5.  Mitochondria: the next (neurode)generation.

Authors:  Eric A Schon; Serge Przedborski
Journal:  Neuron       Date:  2011-06-23       Impact factor: 17.173

6.  Parkin mediates beclin-dependent autophagic clearance of defective mitochondria and ubiquitinated Abeta in AD models.

Authors:  Preeti J Khandelwal; Alexander M Herman; Hyang-Sook Hoe; G William Rebeck; Charbel E-H Moussa
Journal:  Hum Mol Genet       Date:  2011-03-04       Impact factor: 6.150

7.  Bioenergetic mechanisms in astrocytes may contribute to amyloid plaque deposition and toxicity.

Authors:  Wen Fu; Diya Shi; David Westaway; Jack H Jhamandas
Journal:  J Biol Chem       Date:  2015-03-26       Impact factor: 5.157

8.  Effect of α-synuclein on amyloid β-induced toxicity: relevance to Lewy body variant of Alzheimer disease.

Authors:  Rosa Resende; Sueli C F Marques; Elisabete Ferreiro; Isaura Simões; Catarina R Oliveira; Cláudia M F Pereira
Journal:  Neurochem Res       Date:  2013-02-07       Impact factor: 3.996

9.  Single-Base Resolution Mapping of 5-Hydroxymethylcytosine Modifications in Hippocampus of Alzheimer's Disease Subjects.

Authors:  Elizabeth M Ellison; Melissa A Bradley-Whitman; Mark A Lovell
Journal:  J Mol Neurosci       Date:  2017-09-02       Impact factor: 3.444

10.  Intermittent hypoxia training protects cerebrovascular function in Alzheimer's disease.

Authors:  Eugenia B Manukhina; H Fred Downey; Xiangrong Shi; Robert T Mallet
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.